SCHEMBL7173102

SCHEMBL7173102

Cn1cnc2c(NCc3cccc(O)c3)nc(NCCO)nc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 10/20 0.78
CDK2 P24941 6/20 0.78
CCNB2 O95067 6/20 0.78
CCNB1 P14635 6/20 0.78
CCNB3 Q8WWL7 6/20 0.78
CCNE2 O96020 2/20 0.78
CCNE1 P24864 2/20 0.78
CDK5 Q00535 2/20 0.78
CCNA2 P20248 2/20 0.78
CCNA1 P78396 2/20 0.78
TDP1 Q9NUW8 2/20 0.78
KDM4E B2RXH2 1/20 0.78
ALDH1A1 P00352 1/20 0.78
CYP1A2 P05177 1/20 0.78
CYP3A4 P08684 1/20 0.78
GAA P10253 1/20 0.78
CYP2D6 P10635 1/20 0.78
MAPT P10636 1/20 0.78
ALOX15 P16050 1/20 0.78
NFKB1 P19838 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Olomoucine SCHEMBL135056 0.88 CDK1 (1.00) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL7099155 0.83 CDK1 (0.74) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL14182620 0.82 CDK1 (0.87) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL29501842 0.79 CDK2 (0.62) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL449140 0.79 CDK2 (0.62) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL13252976 0.78 CDK1 (0.81) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL448408 0.76 CDK2 (0.58) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL450530 0.75 CDK1 (0.57) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL29501930 0.75 CDK1 (0.57) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL1216905 0.74 CDK1 (1.00) CDK1CDK2CCNB2CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2003-10-02 US claimed
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2002-04-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK2 359/4885CCNB2 456/4885
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK2 359/4885CCNB2 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.